Conditions

This post was originally published on this site I had my six-month checkup with the oncologist a couple of weeks ago. I won’t keep you in suspense: My follicular lymphoma is stable, and things look good. But it was a rough ride getting to the good news. Literally. I made the appointment for 9 a.m.…

This post was originally published on this site The U.S. Food and Drug Admnistration (FDA) has agreed to review Sanofi’s biologics license application (BLA) for its investigational antibody, isatuximab, as a potential therapy for patients with hard-to-treat multiple myeloma, the company announced. FDA’s final decision about whether to approve isatuximab is expected by April 30, 2020, according…

This post was originally published on this site Combining the experimental therapy MDNA55 with anti-cancer interferons (IFNs) can effectively kill cancer cells and extend the survival of mice with metastatic ovarian cancer, new research results show. The study, “Combination immunotherapy with IL-4- Pseudomonas exotoxin and IFN-α and IFN-γ mediate antitumor effects in vitro and in a mouse model…

This post was originally published on this site The Dana-Farber Cancer Institute will get $20 million to create the Saverin Breast Cancer Research Fund aimed at extending the lives of metastatic breast cancer patients. The gift from the “Saverin Family” is the largest individual gift for breast cancer research in the institute’s history. No further…

This post was originally published on this site Alterations in the blood cell count of people with sarcoidosis might indicate that the disease has invaded the bone marrow, a case report suggests. Doctors should therefore consider this clinical sign to aid in early diagnosis and avoid further complications. The study, “Bone marrow involvement in sarcoidosis:…

This post was originally published on this site A genomic rearrangement involving the immunoglobulin lambda (IgL) gene is predictive of resistance to immunomodulatory agents and poor outcomes among multiple myeloma patients, a new study suggests. Testing for this rearrangement of chromosomes may help better stratify patients according to their risk of disease progression and tailor…

This post was originally published on this site Scientists discovered a metabolic enzyme that adds methyl groups to other molecules, called nicotinamide N-methyltransferase, that plays an important role in the progression of high-grade serous carcinoma, the most deadly form of ovarian cancer. The findings of the study, “Proteomics reveals NNMT as a master metabolic regulator…

This post was originally published on this site A combination of Noxopharm’s radiation sensitizer Veyonda (idronoxil) and 177LuPSMA-617 — a kind of targeted radiation therapy — is safe and well-tolerated, and appears to have a high efficacy in men with metastatic castration-resistant prostate cancer (mCRPC), preliminary results from an ongoing Phase 1/2 trial show. The…

This post was originally published on this site I dated a guy in college who described the time he saw a nasty brown stain on his shower floor. When he called his mother, she explained that he would need to clean it with cleanser and a sponge. All his life he assumed that the shower…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) has accepted for review six supplemental biologics license applications (sBLAs) seeking to expand the dosing schedule of Keytruda (pembrolizumab) so the medication can be administered every six weeks. Keytruda is a checkpoint blockade immunotherapy developed by Merck (known as MSD…

This post was originally published on this site Cellectar Biosciences’ investigational radiotherapeutic compound, CLR 131, has received fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The designation will support and help expedite CLR 131’s clinical development, as well as its…